Alcami Announces CEO Transition

Company Leadership Changes - Patrick Walsh, the Chairman of the Board and former CEO of Alcami, has been appointed as Interim CEO following the resignation of Bill Humphries [2] - Patrick Walsh has previously served as CEO of Alcami on two occasions and has been Chairman for the past four years [1] - Patrick Walsh also holds leadership positions at ANI Pharmaceuticals, MedPharm, and is an Operating Partner at Ampersand Capital Partners [1] Company Overview - Alcami is a US-based contract development and manufacturing organization (CDMO) with over 45 years of experience in pharmaceuticals and biologics [3] - The company offers integrated lab services, drug product manufacturing, and cGMP pharma storage and support services, including environmental monitoring, calibration, and validation [3] - Alcami is privately owned by GHO Capital, The Vistria Group, and Ampersand Capital Partners [3] Leadership Transition Commentary - Patrick Walsh expressed gratitude to Bill Humphries for his leadership over the past two years, particularly during a period of facilities expansion and global supply chain realignment [4] - Bill Humphries was recognized for his strong advocacy for clients and his contributions to the organization [4]